Pfizer

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. (NYSE: PFE) heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November

30 November 2025

Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Updated November 30, 2025 Pfizer stock is in the middle of a big reset. The COVID windfall is fading, but a massive obesity-drug acquisition, a landmark bladder‑cancer approval and a high dividend yield are reshaping the story investors see in

30 November 2025

Company News · Investment Analysis · Mergers & Acquisitions · Pharma Industry · Stock Market

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer Inc. (NYSE: PFE) is back in the spotlight as of November 30, 2025. Fresh regulatory filings show new institutional buying, analysts are nudging price targets higher, and the company has closed a multibillion‑dollar obesity deal while reshaping its post‑pandemic

30 November 2025

Dividend Investing · Institutional Investors · NYSE:PFE · Pfizer · Pharmaceutical Industry · Stock Market

Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

Published: November 28, 2025 – mid‑session U.S. trading Pfizer stock price today: PFE edges higher in midday trade Pfizer stock (NYSE: PFE) is trading around $25.8 per share in late morning trading on Friday, November 28, 2025, up roughly 0.3%

28 November 2025

Dividend Stocks · Financial Analysis · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Inc. (NYSE: PFE) spent Wednesday trading slightly lower despite a stream of fresh headlines that cut both ways for sentiment. The stock hovered around $25.7, giving back a fraction of Tuesday’s nearly 2% gain, as investors weighed upbeat news

26 November 2025

Cancer Research · Legal Issues · NYSE:PFE · Obesity · Pharmaceuticals · Stocks

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer Inc. (NYSE: PFE) heads into Wednesday, November 26, 2025 with its share price sitting just under the top of its recent trading range and a narrative that looks very different from the COVID‑era boom and bust. After climbing almost

26 November 2025

Financial Analysis · Health Trends · Investment Strategies · NYSE:PFE · Pharmaceuticals · Stock Market

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer Inc. (NYSE: PFE) is back on many traders’ screens today. As of early afternoon on Tuesday, November 25, 2025, Pfizer shares are trading around $25.65, up roughly 1.7% on the session, after touching an intraday high near $25.96 and

25 November 2025

Health Business · Investment Analysis · NYSE:PFE · Pfizer News · Pharmaceutical Industry · Stock Market

Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

As investors head into the Tuesday, November 25 session, Pfizer Inc. (NYSE: PFE) remains one of Wall Street’s most closely watched healthcare names. After a brutal comedown from its pandemic-era highs, the drugmaker is trying to convince the market that

25 November 2025

Dividends · Investment Strategies · Market Analysis · Pharma Industry · Stocks

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025 Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the

23 November 2025

Business News · Cancer Research · Dividends · Investing · Pharmaceuticals

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer stock heads into the weekend trading just above $25, with investors digesting a busy week of news: a strong Q3 earnings beat, a fresh FDA cancer-drug approval, completion of a multi‑billion‑dollar obesity deal, a new $6 billion bond issue

23 November 2025

Dividends · Financial News · Investments · Pharmaceuticals · Stock Market

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer’s share price is back in the spotlight on Friday, November 21, 2025, as investors digest strong Phase 3 flu-vaccine data, a $6 billion bond sale to fund its obesity-drug deal, and ongoing debate around the company’s roughly 7% dividend

21 November 2025

Dividends · Financial Analysis · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Pfizer has closed its up to $10 billion acquisition of Metsera (MTSR) and raised $6 billion in bonds to help fund the deal. Here’s what today’s developments mean for former Metsera shareholders, Pfizer investors and the future of the obesity

21 November 2025

Financial Analysis · Investment News · Mergers & Acquisitions · NASDAQ:MTSR · NYSE:PFE · Pharma Industry · Stock Market